Related Experiment Video
Updated: Mar 13, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Effect of atorvastatin on serum omentin-1 in patients with coronary artery disease
Qianqian Chen1, Xingchen Shang, Meng Yuan
1Departments of aEmergency bBreast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Insights
Atorvastatin therapy significantly increased serum omentin-1 levels in patients with coronary artery disease (CAD). Higher doses of atorvastatin showed a more pronounced effect, suggesting a dose-dependent relationship in improving this biomarker.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Serum omentin-1 levels are associated with coronary artery disease (CAD).
- Understanding factors influencing omentin-1 is crucial for CAD management.
Purpose of the Study:
- To evaluate the impact of atorvastatin on serum omentin-1 levels in patients with CAD.
- To determine if the effect is dose-dependent.
Main Methods:
- 198 CAD patients (acute coronary syndrome and stable angina pectoris) received atorvastatin (20 or 40 mg/day) for 12 weeks.
- Serum omentin-1 levels were measured at baseline and after treatment.
- Correlations with lipid profiles and inflammatory markers were analyzed.
Main Results:
- Atorvastatin significantly increased serum omentin-1 in both ACS and SAP groups.
- The 40 mg/day dose yielded greater increases than the 20 mg/day dose.
- Increases in omentin-1 inversely correlated with LDL cholesterol, IL-6, and hs-CRP.
Conclusions:
- Atorvastatin effectively raises serum omentin-1 concentrations in CAD patients.
- The effect is dose-dependent, with higher doses showing greater efficacy.
- Omentin-1 changes are linked to reductions in LDL cholesterol and IL-6.
Objective:
An association between coronary artery disease (CAD) and serum omentin-1 was recently identified. The aim of the present study was to investigate the effect of atorvastatin on serum levels of omentin-1 in patients with CAD.
Methods:
One-hundred and ninety-eight patients with CAD were divided into two groups: those with acute coronary syndrome (ACS) and those with stable angina pectoris (SAP). All patients were randomized to receive atorvastatin therapy at a dose of either 20 or 40 mg/day for 12 weeks. Serum omentin-1 levels and other parameters were determined at baseline and at the end of the study.
Results:
Atorvastatin at 20 and 40 mg/day increased serum omentin-1 levels in patients with ACS (20 mg, P=0.007; 40 mg, P<0.001) and in those with SAP (20 mg, P=0.017; 40 mg, P<0.001). Atorvastatin at 40 mg induced greater changes in serum omentin-1 levels compared with 20 mg atorvastatin in both the ACS group (P=0.003) and the SAP group (P=0.012). The increments of serum omentin-1 levels with atorvastatin administration inversely correlated with changes in LDL cholesterol (r=-0.145, P=0.041), interleukin-6 (r=-0.162, P=0.023), and high-sensitivity C-reactive protein (r=-0.185, P=0.009) in patients with CAD. Furthermore, changes in LDL cholesterol (β=-0.158, P=0.027) and interleukin-6 (β=-0.154, P=0.044) remained independent determinants of omentin-1 alterations in standard multiple regression analysis (R=0.122, P=0.006) after adjusting for age, sex, smoking, family history of CAD, and BMI in patients with CAD.
Conclusion:
Atorvastatin increased serum omentin-1 concentrations in patients with CAD in a dose-dependent manner.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:26Coronary Artery Disease II: Pathophysiology
01:26Atherosclerosis III: Management
01:30Coronary Artery Disease I: Introduction
01:30Coronary Artery Disease III: Clinical Manifestations